1st production QuiremSpheres
On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166.
Voor meer informatie: http://www.quirem.com/

Other news

LinkedIn post ESRR2024
📢 Important update on EU #GMP Annex 1 at #ESRR2024! The revised EU GMP Annex 1, effecti...
ABX has received marketing authorisation for the radiotracer Radelumin® in Germany
ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
Interested in a collaboration?
Contact us to discuss the possibilities.